SRPK1‑siRNA suppresses K562 cell growth and induces apoptosis via the PARP‑caspase3 pathway

Wang,Hailian; Ge,Wei; Jiang,Wen; Li,Dong; Ju,Xiuli

doi:10.3892/mmr.2017.8032

SRPK1‑siRNA suppresses K562 cell growth and induces apoptosis via the PARP‑caspase3 pathway

Authors:
- Hailian Wang
- Wei Ge
- Wen Jiang
- Dong Li
- Xiuli Ju
View Affiliations

Affiliations: Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Department of Pediatrics, The Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: November 13, 2017 https://doi.org/10.3892/mmr.2017.8032
Pages: 2070-2076

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Serine-arginine protein kinase 1 (SRPK1) has been used as an important signal mediator, and is associated with cancer development. However, studies have yet to determine whether SRPK1 suppresses leukemia cell growth and induces apoptosis. Studies have also yet to reveal the underlying mechanisms. In the present study, the effects of downregulating SRPK1 gene expression on chronic myeloid leukemia cell lines (K562 cells) were investigated through RNA interference (RNAi) and the proliferation inhibition and apoptosis induction of SRPK1 in K562 cells were analyzed. K562 cells were transfected with two different concentrations of siRNA, and the transfection efficiency was detected via flow cytometry. The expression of SRPK1 was detected via reverse transcription‑quantitative polymerase chain reaction. K562 cell proliferation and apoptosis were analyzed using MTT and flow cytometry respectively. The roles of caspase‑3, poly (ADP‑ribose) polymerase (PARP), p53 and B-cell lymphoma (Bcl)‑2/Bcl‑2 associated X, apoptosis regulator (Bax) proteins in the apoptosis of human K562 cells were further examined through western blot analysis. The SRPK1 expression was lower in the K562 cells transfected with SRPK1‑siRNA compared with untransfected cells. The inhibition rate in the transfected groups was increased compared with the untransfected groups. Compared with control groups, the number of apoptotic cells in the SRPK1‑silenced groups increased. The number of early apoptotic cells also increased. The cleaved caspase‑3, cleaved PARP and p53 expression levels were significantly increased in the RNAi groups compared with control groups. Conversely, the Bcl‑2/Bax rate was significantly lower. In conclusion, the knockdown of the SRPK1 gene by RNAi inhibited the proliferation of K562 cells and induced their apoptosis. Apoptosis was induced by the activation of the PARP‑caspase3 pathway.

View Figures

View References

1	Ding JH, Zhong XY, Hagopian JC, Cruz MM, Ghosh G, Feramisco J, Adams JA and Fu XD: Regulated cellular partitioning of SR protein-specific kinases in mammalian cells. Mol Biol Cell. 17:876–885. 2006. View Article : Google Scholar :
2	Ngo JC, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD and Ghosh G: Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell. 20:77–89. 2005. View Article : Google Scholar
3	Mavrou A, Brakspear K, Hamdollah-zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO and Oltean S: Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 34:4311–4319. 2015. View Article : Google Scholar
4	Hayes GM, Carrigan PE, Beck AM and Miller LJ: Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 66:3819–3827. 2006. View Article : Google Scholar
5	Hayes GM, Carrigan PE and Miller LJ: Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 67:2072–2080. 2007. View Article : Google Scholar
6	Lassus P, Opitz-Araya X and Lazebnik Y: Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science. 297:1352–1354. 2002. View Article : Google Scholar
7	Wurzer WJ, Planz O, Ehrhardt C, Giner M, Silberzahn T, Pleschka S and Ludwig S: Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J. 22:2717–2728. 2003. View Article : Google Scholar :
8	Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, et al: Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 419:395–399. 2002. View Article : Google Scholar
9	Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P and Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 9:347–351. 2003. View Article : Google Scholar
10	Liu J, Liu J, Mao J, Yuan X, Lin Z and Li Y: Caspase-3-mediated cyclic stretch-induced myoblast apoptosis via a Fas/FasL-independent signaling pathway during myogenesis. J Cell Biochem. 107:834–844. 2009. View Article : Google Scholar
11	Jiang J, Qi YX, Zhang P, Gu WT, Yan ZQ, Shen BR, Yao QP, Kong H, Chien S and Jiang ZL: Involvement of Rab28 in NF-κB nuclear transport in endothelial cells. PLoS One. 8:e560762013. View Article : Google Scholar :
12	Rennier K and Ji JY: Effect of shear stress and substrate on endothelial DAPK expression, caspase activity, and apoptosis. BMC Res Notes. 6:102013. View Article : Google Scholar :
13	Xu C, Hao Y, Wei B, Ma J, Li J, Huang Q and Zhang F: Apoptotic gene expression by human periodontal ligament cells following cyclic stretch. J Periodontal Res. 46:742–748. 2011. View Article : Google Scholar
14	Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57:3697–3707. 1997.
15	Forment J, Mulet JM, Vicente O and Serrano R: The yeast SR protein kinase Sky1p modulates salt tolerance, membrane potential and the Trk1,2 potassium transporter. Biochim Biophys Acta. 1565:36–40. 2002. View Article : Google Scholar
16	Kondoh H, Yuasa T and Yanagida M: Mis3 with a conserved RNA binding motif is essential for ribosome biogenesis and implicated in the start of cell growth and S phase checkpoint. Genes Cells. 5:525–541. 2000. View Article : Google Scholar
17	Kamachi M, Le TM, Kim SJ, Geiger ME, Anderson P and Utz PJ: Human autoimmune sera as molecular probes for the identification of an autoantigen kinase signaling pathway. J Exp Med. 196:1213–1225. 2002. View Article : Google Scholar :
18	Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO and Oltean S: Serine arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 34:4311–4319. 2015. View Article : Google Scholar
19	Lin JC, Lin CY, Tarn WY and Li FY: Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events. RNA. 20:1621–1631. 2014. View Article : Google Scholar :
20	Hu ZY, Wang XY, Guo WB, Xie LY, Huang YQ, Liu YP, Xiao LW, Li SN, Zhu HF, Li ZG and Kan H: Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget. 7:11733–11743. 2016. View Article : Google Scholar :
21	Liu H, Hu X, Zhu Y, Jiang G and Chen S: Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells. Tumour Biol. 37:7287–7293. 2016. View Article : Google Scholar
22	Sanidas I, Kotoula V, Ritou E, Daans J, Lenz C, Mairhofer M, Daniilidou M, Kolbus A, Kruft V, Ponsaerts P and Nikolakaki E: The ratio of SRPK1/SRPK1a regulates erythroid differentiation in K562 leukaemic cells. Biochim Biophys Acta. 1803:1319–1331. 2010. View Article : Google Scholar
23	Wu Q, Chang Y, Zhang L, Zhang Y, Tian T, Feng G, Zhou S, Zheng Q, Han F and Huang F: SRPK1 dissimilarly impacts on the growth, metastasis, chemosensitivity and angiogenesis of glioma in normoxic and hypoxic conditions. J Cancer. 4:727–735. 2013. View Article : Google Scholar :
24	van Roosmalen W, Le Dévédec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de Graauw M, et al: Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. J Clin Invest. 125:1648–1664. 2015. View Article : Google Scholar :
25	Wang P, Zhou Z, Hu A, de Albuquerque Ponte C, Zhou Y, Hong L, Sierecki E, Ajiro M, Kruhlak M, Harris C, et al: Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell. 54:378–391. 2014. View Article : Google Scholar :
26	Ren G, Sheng L, Liu H, Sun Y, An Y and Li Y: The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Med Oncol. 32:2092015. View Article : Google Scholar
27	Sigala I, Tsamis KI, Gousia A, Alexiou G, Voulgaris S, Giannakouros T, Kyritsis AP and Nikolakaki E: Expression of SRPK1 in gliomas and its role in glioma cell lines viability. Tumour Biol. 37:8699–8707. 2016. View Article : Google Scholar
28	Decker P and Muller S: Modulating poly (ADP-ribose) polymerase activity: Potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol. 3:275–283. 2002. View Article : Google Scholar
29	Bellodi C, Kopmar N and Ruggero D: Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J. 29:1865–1876. 2010. View Article : Google Scholar :
30	Elkholi R and Chipuk JE: How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis. Bioessays. 36:46–51. 2014. View Article : Google Scholar